CoChat

The DOI matches its Crossref record; 174 of the 175 references it cites were found in a registry or an index.

Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy

Open access
Kopschina Feltes, Paula, Doorduin, Janine, Klein, Hans C, Juárez-Orozco, Luis Eduardo, Dierckx, Rudi AJO, Moriguchi-Jeckel, Cristina M, de Vries, Erik FJ · 2017 · Journal of Psychopharmacology

Abstract

Major depressive disorder (MDD) is a prevalent and disabling psychiatric disease with rates of non-responsiveness to antidepressants ranging from 30–50%. Historically, the monoamine depletion hypothesis has dominated the view on the pathophysiology of depression. However, the lack of responsiveness to antidepressants and treatment resistance suggests that additional mechanisms might play a role. Evidence has shown that a subgroup of depressive patients may have an underlying immune deregulation that could explain the lack of therapeutic benefit from antidepressants. Stimuli like inflammation and infection can trigger the activation of microglia to release pro-inflammatory cytokines, acting on two main pathways: (1) activation of the hypothalamic–pituitary adrenal axis, generating an imbalance in the serotonergic and noradrenergic circuits; (2) increased activity of the enzyme indoleamine-2,3-dioxygenase, resulting in depletion of serotonin levels and the production of quinolinic acid. If this hypothesis is proven true, the subgroup of MDD patients with increased levels of pro-inflammatory cytokines, mainly IL-6, TNF-α and IL-1β, might benefit from an anti-inflammatory intervention. Here, we discuss the pre-clinical and clinical studies that have provided support for treatment with non-steroidal anti-inflammatory drugs in depressed patients with inflammatory comorbidities or an elevated immune profile, as well as evidences for anti-inflammatory properties of standard antidepressants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881117711708

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Hypothesis of immune involvement in the pathophysiology of major depressive disorder. Inflammatory, infectious and stressful challenges might trigger the activation of the resident microglia. Activated microglia produce pro-inflammatory cytokines that can contribute to neurodegeneration and depressive disorders through the hyper-activation of the HPA axis and the increase in indoleamine-2,3-dioxygenase (IDO) enzyme activity. Hyper-activation of the HPA axis leads to the increase of corticotrophin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and cortisol that disturb neurotransmitter homeostasis (mainly noradrenergic and serotonergic systems) and the neuronal growth factor synthesis. IDO decreases the synthesis of serotonin by switching the balance between the production of serotonin from tryptophan and the production of kynurenic acid (KYN) and quinolinic acid (QUIN). Depletion of serotonin leads to depressive symptoms. QUIN acts as a neurotoxin, gliotoxin, pro-inflammatory mediator and can also alter the integrity of the blood–brain barrier (BBB).
Figure 1. Hypothesis of immune involvement in the pathophysiology of major depressive disorder. Inflammatory, infectious and stressful challenges might trigger the activation of the resident microglia. Activated microglia produce pro-inflammatory cytokines that can contribute to neurodegeneration and depressive disorders through the hyper-activation of the HPA axis and the increase in indoleamine-2,3-dioxygenase (IDO) enzyme activity. Hyper-activation of the HPA axis leads to the increase of corticotrophin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and cortisol that disturb neurotransmitter homeostasis (mainly noradrenergic and serotonergic systems) and the neuronal growth factor synthesis. IDO decreases the synthesis of serotonin by switching the balance between the production of serotonin from tryptophan and the production of kynurenic acid (KYN) and quinolinic acid (QUIN). Depletion of serotonin leads to depressive symptoms. QUIN acts as a neurotoxin, gliotoxin, pro-inflammatory mediator and can also alter the integrity of the blood–brain barrier (BBB).CC BY-NC · PubMed Central
Figure 2. Possible anti-inflammatory mechanism of action of antidepressants. Antidepressants that increase the levels of serotonin (i.e. SSRIs) might exert their anti-inflammatory effects by cAMP-mediated pathways. 5-HT increases intracellular cAMP levels via 5-HT receptors linked to G protein-mediated stimulation of adenylyl cyclase, leading to a reduction in the expression of cytokines via inhibition of the protein kinase A (PKA) pathway.
Figure 2. Possible anti-inflammatory mechanism of action of antidepressants. Antidepressants that increase the levels of serotonin (i.e. SSRIs) might exert their anti-inflammatory effects by cAMP-mediated pathways. 5-HT increases intracellular cAMP levels via 5-HT receptors linked to G protein-mediated stimulation of adenylyl cyclase, leading to a reduction in the expression of cytokines via inhibition of the protein kinase A (PKA) pathway.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 174 references

Research works printed but not linked: 3

  1. 10.1177/09680519030090010101 · DOI · Paper page
  2. Maes M, 2008, Neuro Endocrinol Lett, 29, 117
  3. Roomruangwong C, 2016, Mol Neurobiol, 6, 1

Cited by

See all 292

Metadata

Authors
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F.
Affiliations
  • Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, the Netherlands
  • University Medical Center Groningen (NL)
  • Instituto de Geriatria e Gerontologia, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brasil
Venue
Journal of Psychopharmacology
Published
2017-06-27
Volume
31
Issue
9
Pages
1149-1165
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2730275538
Cited by
279
References
175
Citations by year
2026: 19 · 2025: 27 · 2024: 28 · 2023: 41 · 2022: 41 · 2021: 36 · 2020: 39 · 2019: 29 · 2018: 17 · 2017: 2
FWCI
1.62
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
major depressive disorder, treatment-resistant depression, anti-inflammatory therapy, nonsteroidal anti-inflammatory drugs, immune dysregulation, inflammatory cytokines, microglial activation, hypothalamic-pituitary-adrenal axis, indoleamine 2,3-dioxygenase, serotonin depletion, quinolinic acid, inflammatory comorbidities
MeSH terms
Anti-Inflammatory Agents, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Hypothalamo-Hypophyseal System, Inflammation, Pituitary-Adrenal System, Serotonin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. https://app.cochat.ai/papers/10.1177/0269881117711708
The paper
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017). Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117711708

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.